HindawiPublishingCorporationSarcomaVolume2009,ArticleID756395,5pagesdoi:10.1155/2009/756395ClinicalStudySurvivalinMalignantPeripheralNerveSheathTumours:AComparisonbetweenSporadicandNeuroﬁbromatosisType1-AssociatedTumoursD.E.Porter,1V.Prasad,2L.Foster,1G.F.Dall,1R.Birch,3andR.J.Grimer21DepartmentofOrthopaedicSurgery,UniversityofEdinburgh,RoyalInﬁrmaryofEdinburgh,LittleFranceCrescent,EdinburghEH164SU,UK2TheRoyalOrthopaedicHospital,BristolRoadSouth,Northﬁeld,BirminghamB312AP,UK3PeripheralNerveInjuriesUnit,RoyalNationalOrthopaedicHospitalTrust,BrockleyHillStanmore,MiddlesexHA74LP,UKCorrespondenceshouldbeaddressedtoG.F.Dall,gdall@nhs.netReceived2October2008;Accepted5January2009RecommendedbyAlessandroGronchiWestudied123patientswithmalignantperipheralnervesheathtumours(MPNSTs)between1979and2002.However,90occurredsporadicallywhereas33wereassociatedwithneuroﬁbromatosistype1(NF1).SurvivalwascalculatedusingKaplan-MeiersurvivalcurvesandweusedCox’sproportionalhazardsmodeltoidentifyindependentprognosticfactors.A5-yearsurvivalfor110nonmetastaticpatientswas54%;(33%NF1and63%sporadicP=.015).Tumourstageandsiteweresigniﬁcantprognosticindicatorsafterunivariateanalysis.Aftermultivariateanalysis,however,onlyNF1(P=.007)andtumourvolumemorethan200m(P=.015)remainedindependentpredictorsofpooroutcome.WerecommendthatNF1betakenintoaccountduringMPNSTstaging.AsthesurvivalrateintheNFgroupwasdependantontumourvolume,routinescreeningofthesepatientswithFDGPETand/orMRImaybewarranted,therebystagingandcontrollingthemattheearliestpossibleopportunity.Copyright©2009D.E.Porteretal.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.1.IntroductionMalignantperipheralnervesheathtumours(MPNSTs)areaggressive,locallyinvasivesofttissuesarcomas,typicallypresentingasarapidlygrowingandpainfullump.Thesetumoursaccountforupto10%ofallsofttissuesarcomas[1]andareassociatedwithpoorprognosisunlesswideexcisionofthetumourisundertakenbeforelocalinvasionordistantmetastasiscanoccur.TheincidenceofsporadicMPNSTsislow,withalifetimeriskof0.001%[2,3]butinasso-ciationwiththefamilialconditionneuroﬁbromatosistype1(NF1),wherethesetumoursoftenarisefrommalignanttransformationofaplexiformneuroﬁbroma,theincidenceismuchhigher.Evansetal.[4]estimatethelifetimeriskofdevelopingMPNSTsinthepopulationofpatientswithNF1tobeashighas13%.AnumberofstudieshavecomparedsurvivalinsporadicandNF1-associatedtumours[1,4–9]butnoconsensushasbeenreachedonwhetherNF1isanindependentpoorprognosticfactorornot.OurstudyaimedtodeterminefactorsimportanttooutcomeinalargepopulationofpatientswithMPNSTsfromtwoUnitedKingdomcentresforsofttissuetumoursurgery.2.PatientsandMethodsThemedicalrecordsfrom135patientsdiagnosedwithMPNSTstreatedbetween1979and2002attwoUKcenterswerereviewed.In12patients,therewasinsuﬃcientfollow-updataandtheywereexcluded;leaving123patientsthathadfollow-updatafrom6monthsto21yearsandtheywereincludedintheanalysis.PatientswithNF1wereidentiﬁedbythepresenceofcertaincharacteristicfeaturesbasedonthediagnosticcriteriaforNF1[10]includingfeaturessuchascaf´eaulaitspots,Lischnodules,multipleneuroﬁbromata,andapositivefamilyhistory.Astatementinthepatient’smedicalrecordsofanNF1diagnosiswasacceptedassuﬃcientevidenceforthatindividualtobeplacedintheNF1group.2SarcomaHistopathologistssittingonthenationalmusculoskeletaltumourpanelconﬁrmedthediagnosesofMPNSTsandusedtheTrojanisystemtohistologicalygradethetumours.ThedateofdiagnosistakentobethedateofﬁrstbiopsyorexcisionfromwhichahistologicaldiagnosisofMPNSTswasmade.Operationnotesandhistologyreportswereutilisedtodeterminetheextentofsurgeryandthemarginsachieved.Forthepurposesofthisanalysis,amputationorwideexcisionwasdeemedtogiveadequateclearance;marginalexcisionanddebulkingweredeemedtogiveinadequateclearancemargins.Chemotherapyandradiotherapyintentsweredocumentedandtumoursizeandvolumewerecalculatedusingsurgicalormagneticresonanceimagingrecords.SurvivaldatawascalculatedusingKaplan-MeiercurvesandmultivariateanalysiswasperformedusingCox’spropor-tionalhazardsmodelusingthestatisticalpackageSPSS13.0.Theeﬀectofeachvariablewascomparedtotheeﬀectofthegroupasawhole.3.ResultsOfthe123patientsinthisstudywithMPNSTs,33patients(27%)hadNF1.NF1patientsweresigniﬁcantlyyoungeratdiagnosisthanthosewithsporadictumourswithamedianageof26yearscomparedwith53yearsforsporadicMPNSTs,(X2=23.65,P<.001).TherewerealsosigniﬁcantdiﬀerencesinthedistributionofthesiteoftumoursbetweenthetwogroupswithrelativeoverrepresentationofperipherallimbtumoursinthesporadicgroupandaxialtumoursintheNF1group(X2=24.3,P<.001)(seeFigure1).TherewerenosigniﬁcantdiﬀerencesinthetumourvolumesfoundintheNF1andsporadicgroups(P=.36).Overall5-yearsurvivalforall123patientswas51%andwassigniﬁcantlyworseforpatientswithNF1thanthosewithsporadicMPNSTs(32%versus60%;P=.01).13patients(11%)hadIUCC-TNMstageIVdisease(metastasesatdiagnosis).StageIVdiseasewasmorecommoninNF1patients(15%)thanthosewithsporadictumours(9%)butNF1wasstillassociatedwithasigniﬁcantlyworse5-yearsurvivalifpatientswithstageIVdiseasewereremovedfromtheanalysis(33%versus63%;P=.015)(seeFigure2).Theeﬀectofotherfactorsonsurvivalinthegroupofpatientswithoutmetastasesatdiagnosiswasinvesti-gatedusingKaplan-MeieranalysisandisdocumentedinTable1.TwofactorsremainedsigniﬁcantonmultivariateCoxregressionanalysis.Tumourswithvolume<200mlhadasigniﬁcantlybetterprognosis(HR0.355,95%CI0.15–0.82,P=.015)thanlargertumours,andNF1tumourswereassociatedwithsigniﬁcantlypoorerprognosiscomparedwiththoseoccurringsporadically(HR1.811,95%CI1.175–2.791,P=.007).Localtreatmentincludedsurgeryin94%andradiother-apyin61%.Chemotherapywasgivenin26%.2/33(94%)oftheNF1groupand5/90(94%)ofthenon-NF1groupreceivedsurgery.20/33(65%)oftheNF1groupand55/90OtherLumbo-sacralplexusBrachialplexusUpperlimbLowerlimbSiteNF1Sporadic051015202530354045(%)Figure1:Tumourfrequencybysite.6050403020100Follow-up(months)NF1SporadicNF1-censoredSporadic-censored00.20.40.60.81CumulativesurvivalFigure2:Kaplan-Meiersurvivalinpatientswithoutmetastasesatdiagnosis.(61%)ofnon-NF1groupreceivedradiotherapy.Thetypeoftreatmenthadnosigniﬁcanteﬀectonsurvival.AdequateexcisionmarginswereachievedinasimilarproportionofNF1andsporadictumours(31%versus28%).Localrecurrenceoccurredin24patients.Wheresurgerywasattempted,adequatesurgicalmarginswereachievedin28%ofpatients,6%ofwhomdevelopedlocalrecurrence.Intheremaining72%ofpatientsinwhomadequatesurgicalmarginswerenotachieved,thelocalrecurrenceratewas30%.Thisdiﬀerenceinlocalrecurrencewasstatisticallysigniﬁcantusingthechi-squaretest(P<.001).Althoughpatientswithlocalrecurrencedisplayedatrendtowardsworsesurvival,thisdidnotreachstatisticalsigniﬁcance.Atrendwasobservedtowardsworselocalrecurrence-freesurvivalinNF1(5-yearsurvival70%versus81%insporadictumours)butthisdidnotreachstatisticalsigniﬁcance.Sarcoma3Table1:Univariateanalysistodeterminefactorssigniﬁcantforsurvivalinpatientswithoutmetastasesatdiagnosis.FactorNF1SporadicAllpatients5yearsurvival(%)P5yearsurvival(%)P5yearsurvival(%)PStage1100100100246.2.37576.1.07971.1.033SiteLowerlimb55.669.466.7Upperlimb10083.390.9Brachialplexus42.975.068.4Sciaticplexus50.0.139100.03588.9.036Volume<200ml57.185.782.9>200ml50.0.11966.7.01563.6.002GradeLow44.474.270.0High50.0.86279.2.71373.4.606DepthSubcutaneous50.090.083.3Deep50.0.37276.1.75572.2.5714.DiscussionDuetotherelativerarityofMPNSTs,therehavebeenfewlargestudiesintosurvivalandthosereporting5-yearsurvivallackconsistency,withsurvivalratesintherangeof39–85%[6,11].Ouroverallsurvivalof51%iswithinthisrange.ThereisasimilarlackofconsensusontheissueofwhetherornotNF1isanindependentindicatorofpoorprognosis.Anumberofstudiesreportnosigniﬁcantdiﬀerencebetweenthe2groups[1,6,11,12].Others,includingthisstudyreportapooreroutcomeinpatientswithNF1[13–18].IthasbeensuggestedthatpatientswithNF1aremorelikelytopresentlatewithMPNSTsbecausetheymaynotbeasconcernedbytheappearanceofnewswellingsastherestofthepopulation.Inourstudy,agreaterpercentageofNF1patientshadmetastaticdiseaseatpresentation(15%versus9%)butevenwiththeexclusionofthesecasesfromtheanalysis,ourstudyoftheremaining110patientsdemonstrated5-yearsurvivalratesinNF1patientsonlyhalfasgoodasinpatientswithsporadictumours.NF1wasalsoanindependentpredictorofpoorprognosisonmultivariateanalysis.PossibleexplanationsforthepoorerprognosisseeninNF1patientsincludediﬀerencesinthegeneticproﬁleoftumoursarisinginthese2groups[19–21]whichmightaﬀectaggressivepotential.Othercancerssuchasbreastandovariancancershavealsoshownworseprognosisinfamilialcasescomparedtothoseoccurringsporadically[20,22].ReportsthatpatientswithNF1haveanestimatedlifetimeriskofdevelopingMPNSTsinexcessof10%[4],inconjunctionwithourﬁndingsofsigniﬁcantlypoorersurvivalinNF1,underlinetheriskposedbythesetumours,andthedangerofcomplacencyaboutnewepisodesofpainorswellingsintheseindividuals.ThisreportclearlydemonstratesthatpatientswithNF1arediagnosedwithmalignancyatasigniﬁcantlyyoungeragethaninthosewithsporadictumoursandisconsistentwithotherstudies[3,5,9].ThisreﬂectsthenatureofNF1asafamilialneoplastictraitthatpredisposestobothbenignandmalignanttumours.TheNF1genewasidentiﬁedin1987[23]andfunctionsasatumoursuppressorgene.Otherfamilialneoplastictraitsalsoexhibitage-dependentmalignantchangeatayoungeragethaninthegeneralpopulation[20,21].Onunivariateanalysis,thetumourvolume,stage,andsitewerealsofoundtobesigniﬁcantpredictorsofsurvival.Tumourvolumewastheonlyotherfactorthat,togetherwithNF1,remainedsigniﬁcantonmultivariateanalysis.Histologicalgradewasnotfoundtocorrelatewithsurvival;however,theresultmayhavebeenskewedduetosmallnumbers(15/129)oflow-gradetumours.RecentpublisheddatafromHageletal.[21]supportourﬁndingsthattheNF1groupisyounger,hasmoreaxiallylocatedtumours,andhasaworseprognosis.Interestingly,theypresentedevidencethatthehistopathologyofNF1-associatedtumoursdiﬀersfromthesporadictype.Thismayexplainwhywedidnotseeacorrelationbetweenhistologicalgradeandsurvival.TheypostulatedthatandifanewgradingsystemincludedNF1asanindependentprognosticator,thenperhapsgradeandsurvivalwouldcorrelate.TherewasnoobservablediﬀerencebetweentumourvolumesinthesporadicandNF1groups(P=.36).Independentofbiology,asmallvolumetumouroﬀersabetterprognosisbecauseofthehigherchanceofachievingwideresectionmargins.Wefoundthattumoursaﬀectingtheperipheralportionoftheupperlimbwereassociatedwiththebestsurvivalonunivariateanalysis.Interestingly,tumourssitedinthelumbosacralplexusalsoseemedtohaveafavourableprog-nosis.Sincethisgrouprepresentsonly11%ofthetotal,however,thisﬁndingshouldbeinterpretedwithcaution.PeripherallowerlimbtumoursaccountedforthegreatestproportionoftumoursfromtheNF1group(32%)andformedthemajority(58%)oflargevolumetumours.Thesepoorprognosticcofactorsinourgroupoflowerlimbtumourscausetheunivariatesite-speciﬁcsurvivaldiﬀer-encestodisappearonmultivariateanalysis.Otherstudieshavereportedthatperipheralratherthancentrallylocatedtumourshavebettersurvivalrates[11,15].Thisislikelyto4Sarcomaresultfromthesetumoursbeingmoreamenabletoresectionwithwidemarginsormaybebecausetheyaredetectedearlier.Recently,specialistcentershavebeenusingpositronemissiontomographytodetect18F-ﬂuorodeoxyglucose(FDGPET)uptakeinthesetumours.Fisheretal.[24]showedthatFDGPETisausefultoolinmonitoringclinicallystableNF1patientswithplexiformneuroﬁbromasasitcouldpredictwhichweremorelikelytosubsequentlygrowrapidly.AlsoBrenneretal.[25]foundthatinNF1patientswithMPNSTs,higheruptakesduringFDGPETwereassociatedwithsigniﬁcantlyworsesurvivalwhilsthistopathologicaltumourgradingdidnotpredictoutcome.DeﬁnitivetreatmentforMPNSTsinvolvessurgicalremovalofthetumour.Adjuvantorneoadjuvanttherapyisincreasinglyconsideredbuthasnotbeenshowntoconsistentlyimprovesurvival[11,26].Onlyﬁvepatientsinthisstudydidnotreceivesomeformofsurgicaltreatment.Itiswelldocumentedthatthesetumourscanextendconsiderabledistancesalongnervesandifsuspected,afrozensectionshouldbecarriedoutattheproximalanddistallimitsofnerveresectiontoensureclearmargins.Adequatesurgicalmarginswereachievedin31outof118patients(26%)andonly6%ofthesepatientsdevelopedlocalrecurrenceoftheirtumour,incontrastto30%ofpatientsinwhichclearancemarginsweredeemedinadequate.Whenlocalrecurrencedidoccur,thiswasassociatedwithaworseoutcomebutthetrenddidnotreachstatisticalsigniﬁcance.Otherstudiesreportthatthefailuretoachievelocalcontrolofthetumourbearsamajorassociationwithtreatmentfailureandpooroutcome[26,27].AnypatientwithanMPNSTinassociationwithNF1shouldbecarefullystagedpriortotreatmentandshouldbemanagedbyamultidisciplinaryteamfamiliarwithbothsofttissuesarcomasandNF1.Inthosepatientswhoweretreatedwithcurativeintentandhadamarginalresection,recurrenceratesremainedlow3/32.Therefore,werecommendthatpostoperativesurveillanceshouldremaininaccordancewithcurrentNICEsarcomaguidelines[28]andNF1conferencestatement[10].WeconcludethatasNF1isanindependentindicatorofpoorprognosisinMPNSTs,werecommendthatthismustbetakenintoaccountduringthetumourstaging.ItmaybenecessarytohaveseparatestagingsystemsforsporadicandNF1-associatedtumourstoreﬂectthis.AsthesurvivalrateintheNFgroupwasdependantontumourvolume,routinescreeningofthesepatientswithFDGPETandorMRImaybewarranted,therebystagingandcontrollingthemattheearliestpossibleopportunity.References[1]P.F.Doorn,W.M.Molenaar,J.Buter,andH.J.Hoekstra,“Malignantperipheralnervesheathtumorsinpatientswithandwithoutneuroﬁbromatosis,”EuropeanJournalofSurgicalOncology,vol.21,no.1,pp.78–82,1995.[2]R.E.FernerandD.H.Gutmann,“Internationalconsensusstatementonmalignantperipheralnervesheathtumorsinneuroﬁbromatosis,”CancerResearch,vol.62,no.5,pp.1573–1577,2002.[3]B.S.Ducatman,B.W.Scheithauer,D.G.Piepgras,H.M.Reiman,andD.M.Ilstrup,“Malignantperipheralnervesheathtumors.Aclinicopathologicstudyof120cases,”Cancer,vol.57,no.10,pp.2006–2021,1986.[4]D.G.R.Evans,M.E.Baser,J.McGaughran,S.Sharif,E.Howard,andA.Moran,“Malignantperipheralnervesheathtumoursinneuroﬁbromatosis1,”JournalofMedicalGenetics,vol.39,no.5,pp.311–314,2002.[5]R.H.Hruban,M.H.Shiu,R.T.Senie,andJ.M.Woodruﬀ,“Malignantperipheralnervesheathtumorsofthebuttockandlowerextremity.Astudyof43cases,”Cancer,vol.66,no.6,pp.1253–1265,1990.[6]I.M.Ariel,“Tumorsoftheperipheralnervoussystem,”SeminarsinSurgicalOncology,vol.4,no.1,pp.7–12,1988.[7]B.Raney,L.Schnaufer,M.Ziegler,J.Chatten,P.Littman,andP.Jarrett,“Treatmentofchildrenwithneurogenicsarcoma.ExperienceattheChildren’sHospitalofPhiladelphia,1958–1984,”Cancer,vol.59,no.1,pp.1–5,1987.[8]M.Bojsen-MollerandO.Myhre-Jensen,“Aconsecutiveseriesof30malignantschwannomas.Survivalinrelationtoclinico-pathologicalparametersandtreatment,”ActaPathologicaMicrobiologicaetImmunologicaScandinavicaA,vol.92,no.3,pp.147–155,1984.[9]J.E.Wanebo,J.M.Malik,S.R.VandenBerg,H.J.Wanebo,N.Driesen,andJ.A.Persing,“Malignantperipheralnervesheathtumors:aclinicopathologicstudyof28cases,”Cancer,vol.71,no.4,pp.1247–1253,1993.[10]D.A.Stumpf,J.F.Alksne,J.F.Annegers,etal.,“Neuroﬁbro-matosis.Conferencestatement.NationalInstitutesofHealthConsensusDevelopmentConference,”ArchivesofNeurology,vol.45,no.5,pp.575–578,1988.[11]D.V.Cashen,R.C.Parisien,K.Raskin,F.J.Hornicek,M.C.Gebhardt,andH.J.Mankin,“Survivaldataforpatientswithmalignantschwannoma,”ClinicalOrthopaedicsandRelatedResearch,vol.426,pp.69–73,2004.[12]M.Anghileri,R.Miceli,M.Fiore,etal.,“Malignantperipheralnervesheathtumors:prognosticfactorsandsurvivalinaseriesofpatientstreatedatasingleinstitution,”Cancer,vol.107,no.5,pp.1065–1074,2006.[13]R.N.Nambisan,U.Rao,R.Moore,andC.P.Karakousis,“Malignantsofttissuetumorsofnervesheathorigin,”JournalofSurgicalOncology,vol.25,no.4,pp.268–272,1984.[14]T.R.Loree,J.H.NorthJr.,B.A.Werness,R.Nangia,A.P.Mullins,andW.L.HicksJr.,“Malignantperipheralnervesheathtumorsoftheheadandneck:analysisofprognosticfactors,”Otolaryngology—HeadandNeckSurgery,vol.122,no.5,pp.667–672,2000.[15]T.Zeytoonjian,H.J.Mankin,M.C.Gebhardt,andF.J.Hornicek,“Distallowerextremitysarcomas:frequencyofoccurrenceandpatientsurvivalrate,”FootandAnkleInternational,vol.25,no.5,pp.325–330,2004.[16]T.Watanabe,Y.Oda,S.Tamiya,N.Kinukawa,K.Masuda,andM.Tsuneyoshi,“Malignantperipheralnervesheathtumours:highKi67labellingindexisthesigniﬁcantprognosticindica-tor,”Histopathology,vol.39,no.2,pp.187–197,2001.[17]B.C.Ghosh,L.Ghosh,A.G.Huvos,andJ.G.Fortner,“Malignantschwannoma.Aclinicopathologicstudy,”Cancer,vol.31,no.1,pp.184–190,1973.[18]P.P.Sordillo,L.Helson,S.I.Hajdu,etal.,“Malignantschwannoma—clinicalcharacteristics,survival,andresponsetotherapy,”Cancer,vol.47,no.10,pp.2503–2509,1981.Sarcoma5[19]R.S.BridgeJr.,J.A.Bridge,J.R.Neﬀ,S.Naumann,P.Althof,andL.A.Bruch,“Recurrentchromosomalimbalancesandstructurallyabnormalbreakpointswithincomplexkaryotypesofmalignantperipheralnervesheathtumourandmalignanttritontumour:acytogeneticandmolecularcytogeneticstudy,”JournalofClinicalPathology,vol.57,no.11,pp.1172–1178,2004.[20]P.Møller,˚A.Borg,D.G.Evans,etal.,“Survivalinprospectivelyascertainedfamilialbreastcancer:analysisofaseriesstratiﬁedbytumourcharacteristics,BRCAmutationsandoophorec-tomy,”InternationalJournalofCancer,vol.101,no.6,pp.555–559,2002.[21]C.Hagel,U.Zils,M.Peiper,etal.,“HistopathologyandclinicaloutcomeofNF1-associatedvs.sporadicmalignantperipheralnervesheathtumors,”JournalofNeuro-Oncology,vol.82,no.2,pp.187–192,2007.[22]P.D.P.Pharoah,D.F.Easton,D.L.Stockton,S.Gayther,andB.A.J.Ponder,“Survivalinfamilial,BRCA1-associated,andBRCA2-associatedepithelialovariancancer,”CancerResearch,vol.59,no.4,pp.868–871,1999.[23]B.R.Seizinger,G.A.Rouleau,L.J.Ozelius,etal.,“GeneticlinkageofvonRecklinghausenneuroﬁbromatosistothenervegrowthfactorreceptorgene,”Cell,vol.49,no.5,pp.589–594,1987.[24]M.J.Fisher,S.Basu,E.Dombi,etal.,“Theroleof[18F]-ﬂuorodeoxyglucosepositronemissiontomographyinpredict-ingplexiformneuroﬁbromaprogression,”JournalofNeuro-Oncology,vol.87,no.2,pp.165–171,2008.[25]W.Brenner,R.E.Friedrich,K.A.Gawad,etal.,“PrognosticrelevanceofFDGPETinpatientswithneuroﬁbromatosistype-1andmalignantperipheralnervesheathtumours,”EuropeanJournalofNuclearMedicineandMolecularImaging,vol.33,no.4,pp.428–432,2006.[26]K.Leroy,V.Dumas,N.Martin-Garcia,etal.,“Malignantperipheralnervesheathtumorsassociatedwithneuroﬁbro-matosistype1:aclinicopathologicandmolecularstudyof17patients,”ArchivesofDermatology,vol.137,no.7,pp.908–913,2001.[27]M.Carli,A.Ferrari,A.Mattke,etal.,“Pediatricmalignantperipheralnervesheathtumor:theItalianandGermanSoftTissueSarcomaCooperativeGroup,”JournalofClinicalOncology,vol.23,no.33,pp.8422–8430,2005.[28]NHSNationalInstituteforHealthandClinicalExcellence,“ImprovingOutcomesforPeoplewithSarcoma.TheMan-ual,”March2006,http://www.nice.org.uk/nicemedia/pdf/SarcomaFullGuidance.pdf.